Prospera ProReach Program | Natera

 

The ProReach Program

Remote care for Prospera patients including routine labs, in partnership with a premier national diagnostics laboratory.

Natera’s new ProReach Program enables you to stay closely connected with your transplant patients. Leveraging our nationwide mobile phlebotomy network and partnership with a premier national laboratory, we are now able to draw both Prospera and routine labs remotely, including:

  • Blood count such as: CBC, Comprehensive Metabolic Panel, Hemoglobin A1c, Lipid Panel Magnesium, Phosphate, Uric Acid
  • Drug levels such as: Cyclosporin, Everolimus, Sirolimus & Tacrolimus
  • Urinalysis
  • Viral studies such as: BK Virus, COVID Antibody, Cytomegalovirus, Epstein-Barr Virus

ProReach can uniquely benefit your transplant patients. Sign up below for a one-on-one Q&A.

Learn more about ProReach: Watch now


Provider setup in two simple steps


Customize how you follow your transplant patients:

  1. Place Prospera orders in the Provider Portal, and indicate mobile draw
     
  2. Inform your Natera Nurse Coordinator of which patients you’d like to ADD routine lab work throughout national laboratory partner
    • Option 1: Add routine labs on ALL Prospera patients
    • Option 2: Include routine labs on SPECIFIC Prospera patients

 


After enrollment, what’s next?

Once your patients are enrolled in the ProReach Program, Natera will take care of the rest:


OUTREACH

Collect completed requisition forms from center and mails kits to patient's home.

SCHEDULE

Schedule a mobile phlebotomy visit based on the patients preferred availability.

SHIPPING

Coordinate shipping of labs to Natera and our partner lab.

RESULTS

Provide timely Prospera results through your standard delivery channels. Routine lab results provided by partner laboratory.


Complete care with Prospera enables you to:

  • Catch all rejection types in a single blood draw:
    Prospera’s unique ability to identify T cell-mediated rejection gives a more holistic view of your patient’s rejection status.1
  • Minimize risk of missing active rejection:
    Prospera is three times less likely to miss an active rejection* than the firstgeneration donor-derived cell-free DNA test (Negative Predictive Value of 95% vs 84%).1,2
  • More accurately classify active rejection:
    Prospera demonstrated better performance than the first-generation dd-cfDNA test (sensitivity of: 89% vs 59%) to identify patients with active rejection.1,2

 

* 25% prevalence of active rejection
1 Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.
2 Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.

This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485, and CLIA certified. © 2019 Natera, Inc.  All Rights Reserved.